Is This Stock a Screaming Buy: Acura Pharmaceuticals, Inc. (NASDAQ:ACUR)

Equity Research firms currently have a positive stance on shares of Acura Pharmaceuticals, Inc. (NASDAQ:ACUR). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $6.00 on a short term basis.

At the time of writing, the stock was trading at $1.56. This represents a change from the opening price of 1.30%. In terms of performance, year to date, the stock is -39.20%. The monthly stock performance comes in at -5.00%. For the quarter, shares are performing at -16.94%. Weekly performance analysis shows the equity at -4.99%.

In taking a look at technical levels, shares are trading -7.46% away from the 50 day simple moving average and -27.52% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -55.68% away from it’s 52- week high and 11.43% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Acura Pharmaceuticals, Inc.’s RSI stands at 45.30. In looking at volatility levels, the shares saw weekly volatility of 6.15% and 8.66% over the past month.

Leave a Comment